Source:http://linkedlifedata.com/resource/pubmed/id/19074072
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:dateCreated |
2008-12-16
|
pubmed:abstractText |
Relapse of primary disease and occurrence of new cancers can cause significant morbidity and mortality in recipients of autologous and allogeneic hematopoietic-cell transplantation (HCT). Treatment options for relapse are generally limited and can include disease-specific chemotherapy or targeted therapy. Additional relapse-directed therapies that are available for allogeneic HCT recipients include withdrawal of immunosuppression and donor lymphocyte infusion. Selected patients can be offered a second transplant procedure. Newer strategies to eliminate minimal residual disease and, in allogeneic HCT recipients, to augment the graft-versus-tumor effect are needed for patients who are at high risk for relapse after HCT. Second cancers after HCT include post-transplant lymphoproliferative disorder, hematologic malignancies and new solid cancers. The incidence of second solid cancers continues to rise without a plateau with increasing follow up of HCT survivors. Secondary myelodysplastic syndrome and acute leukemia are almost exclusively seen in autologous HCT recipients while post-transplant lymphoproliferative disorders complicate recipients of allogeneic HCT. Appropriate screening evaluations should be performed in HCT survivors to facilitate early detection and treatment of second cancers.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:status |
MEDLINE
|
pubmed:issn |
1520-4391
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
142-9
|
pubmed:meshHeading |
pubmed-meshheading:19074072-Child,
pubmed-meshheading:19074072-Hematologic Neoplasms,
pubmed-meshheading:19074072-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:19074072-Humans,
pubmed-meshheading:19074072-Lymphocyte Transfusion,
pubmed-meshheading:19074072-Multiple Myeloma,
pubmed-meshheading:19074072-Neoplasm Recurrence, Local,
pubmed-meshheading:19074072-Neoplasms,
pubmed-meshheading:19074072-Neoplasms, Second Primary,
pubmed-meshheading:19074072-Recurrence,
pubmed-meshheading:19074072-Risk Factors,
pubmed-meshheading:19074072-Transplantation, Homologous
|
pubmed:year |
2008
|
pubmed:articleTitle |
Old and new cancers after hematopoietic-cell transplantation.
|
pubmed:affiliation |
Blood and Marrow Transplant Program, University of Minnesota, Center for International Blood and Marrow Transplant Research, Minneapolis, MN 55455, USA. majha001@umn.edu
|
pubmed:publicationType |
Journal Article
|